Status:
TERMINATED
Pradaxa (Dabigatran Etexilate) VTE Prevention After Elective Total Hip or Knee Replacement Surgery
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Venous Thromboembolism
Arthroplasty, Replacement
Eligibility:
All Genders
18-99 years
Brief Summary
an open, prospective, observational study to collect data on safety (major bleeding events) and efficacy (symptomatic venous thromboembolism(VTE)) of a switch from Enoxaparin to dabigatran etexilate i...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- patients age 18 years or above undergoing elective total hip or knee replacement surgery
- Exclusion criteria:
- according to the label recommendation for Pradaxa 220 mg QD
Exclusion
Key Trial Info
Start Date :
August 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 21 2011
Estimated Enrollment :
167 Patients enrolled
Trial Details
Trial ID
NCT01153698
Start Date
August 1 2010
End Date
December 21 2011
Last Update
October 3 2023
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
1160.118.43004 Boehringer Ingelheim Investigational Site
Braunau am Inn, Austria
2
1160.118.43002 Boehringer Ingelheim Investigational Site
Ehebichl, Austria
3
1160.118.43005 Boehringer Ingelheim Investigational Site
Graz, Austria
4
1160.118.43016 Boehringer Ingelheim Investigational Site
Stolzalpe, Austria